All New Cases & Investigations

Alexandria Real Estate Equities, Inc. Class Action Lawsuit

U.S. Securities Litigation

Leadership Deadline: January 26, 2026

Alexandria Real Estate Equities, Inc. (NYSE: ARE): Alexandria Real Estate Equities, Inc. has been sued for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws. The decline in Alexandria Real Estate’s share price caused significant losses to investors. The class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities. The class action is pending in the U.S. District Court for the Central District of California and is captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv- 11319.

If you lost money on your investments in Alexandria Real Estate, you are encouraged to submit your information.

Why Was Alexandria Real Estate Sued for Securities Fraud?

Alexandria Real Estate is a real estate investment trust. Its tenants are concentrated in life science industries, such as pharmaceutical and biotechnology companies.

During the relevant period, Alexandria Real Estate touted its leasing volume and development pipeline, specifically regarding a property in Long Island City, New York, stating that leasing volume was “solid” and its pipeline was “well positioned to capture future demand when expansion needs arise.”

As alleged, in truth, Alexandria Real Estate was experiencing lower occupancy rates and slower leasing activity such that it was required to take a real estate impairment charge of $323.9 million with $206 million attributed to its Long Island City property.

Why did Alexandria Real Estate’s Stock Drop?

On October 27, 2025, Alexandria Real Estate announced results below expectations for 3Q 2025 and cut guidance for the remainder of the fiscal year. The company attributed the results to lower occupancy rates and slower leasing activity. It also announced a real estate impairment charge of $323.9 million with $206 million attributed to its Long Island City property, stating that the property was not a life science destination that could scale. Alexandria Real Estate also announced additional impairment charges that may be recognized in 4Q 25 ranging from $0 to $685 million. This news caused the price of Alexandria Real Estate stock to drop $14.93 per share, or more than 19%, from a closing price of $77.87 per share on October 27, 2025, to $62.94 per share on October 28, 2025.

What is the Alexandria Real Estate Leadership Deadline?

You may ask the Court no later than January 26, 2026, which is the first business day after 60 days from the date of the publication of notice of pendency of the action, to appoint you as Lead Plaintiff through counsel of your choice. To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

Contact Us

If you lost money when Alexandria Real Estate securities dropped in price, you are encouraged to submit your information to speak with an attorney about your rights.

You can also contact:
Ross Shikowitz
ross@bfalaw.com
212.789.3619

All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

Attorney advertising. Past results do not guarantee future outcomes.

Photo of Adam C. McCall
Adam C. McCall Associate